Menu Search
Equities

Jazz Pharmaceuticals PLC

J7Z:BRN

Jazz Pharmaceuticals PLC

Actions
  • Price (CHF)104.98
  • Today's Change0.00 / 0.00%
  • Shares traded50.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Jazz Pharmaceuticals PLC grew revenues 4.78% from 3.66bn to 3.83bn. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 224.06m to a profit of 414.83m.
Gross margin89.37%
Net profit margin11.65%
Operating margin16.24%
Return on assets3.97%
Return on equity12.09%
Return on investment4.46%
More ▼

Cash flow in USDView more

In 2023, Jazz Pharmaceuticals PLC increased its cash reserves by 70.88%, or 624.83m. The company earned 1.09bn from its operations for a Cash Flow Margin of 28.48%. In addition the company used 163.06m on investing activities and also paid 305.25m in financing cash flows.
Cash flow per share16.85
Price/Cash flow per share6.78
Book value per share69.01
Tangible book value per share-45.96
More ▼

Balance sheet in USDView more

Jazz Pharmaceuticals PLC has a Debt to Total Capital ratio of 59.44%, a lower figure than the previous year's 146.47%.
Current ratio4.26
Quick ratio3.74
Total debt/total equity1.47
Total debt/total capital0.5944
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-3.53
EPS (TTM) vs
TTM 1 year ago		709.80
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.